These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19671093)

  • 1. Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.
    Brochstein JA; Grupp S; Yang H; Pillemer SR; Geba GP
    Pediatr Transplant; 2010 Mar; 14(2):233-41. PubMed ID: 19671093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease.
    Adkins D; Ratanatharathorn V; Yang H; White B
    Transplantation; 2009 Jul; 88(2):198-202. PubMed ID: 19623014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients.
    Pruett TL; McGory RW; Wright FH; Pescovitz MD; Yang H; McClain JB
    Transplant Proc; 2009 Nov; 41(9):3655-61. PubMed ID: 19917362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
    Willemze R; Richel DJ; Falkenburg JH; Hale G; Waldmann H; Zwaan FE; Fibbe WE
    Bone Marrow Transplant; 1992 Apr; 9(4):255-61. PubMed ID: 1600413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
    Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of anti-CD25 monoclonal antibody used in treating steroid-resistant acute graft-versus-host disease following haploidentical bone marrow transplantation].
    Liu J; Wang HX; Duan LN; Yang HM; Xue M; Zhu L; Ding L; Wang ZD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):160-3. PubMed ID: 19236770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study.
    Goyal RK; Lin Y; Schultz KR; Ferrell RE; Kim Y; Fairfull L; Livote E; Yanik G; Atlas M
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):927-936.e1. PubMed ID: 20100586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of the NIH consensus criteria in children with chronic graft-versus-host disease.
    Lee JW; Lee DH; Jang PS; Yi MS; Chung NG; Cho B; Jeong DC; Kim HK
    Yonsei Med J; 2011 Sep; 52(5):779-86. PubMed ID: 21786443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.
    Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M
    Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.
    Langley RG; Papp K; Bissonnette R; Toth D; Matheson R; Hultquist M; White B
    Int J Dermatol; 2010 Jul; 49(7):818-28. PubMed ID: 20618506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease.
    Hervé P; Flesch M; Tiberghien P; Wijdenes J; Racadot E; Bordigoni P; Plouvier E; Stephan JL; Bourdeau H; Holler E
    Blood; 1992 Jun; 79(12):3362-8. PubMed ID: 1596576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival.
    Goussetis E; Paisiou A; Kitra V; Peristeri I; Vessalas G; Stefanaki K; Panayotou I; Giamaiou K; Kontou E; Kitzoni M; Dimopoulou MN; Karkelis S; Kafritsa Y; Rapsomaniki E; Papassotiriou I; Tsirigotis P; Roma E; Graphakos S
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1058-66. PubMed ID: 21073975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients.
    Racadot E; Milpied N; Bordigoni P; Cahn JY; Plouvier E; Lioure B; Lutz P; Wijdenes J; Herve P
    Bone Marrow Transplant; 1995 May; 15(5):669-77. PubMed ID: 7670394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation.
    Scholl S; Sayer HG; Mügge LO; Kasper C; Pietraszczyk M; Kliche KO; Clement JH; Höffken K
    J Cancer Res Clin Oncol; 2004 Dec; 130(12):704-10. PubMed ID: 15365821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.